Sugi Predict

Sugi Predict / Compounds / SCHEMBL18345386

SCHEMBL18345386

SCHEMBL18345386

CC1=NN(C)C(=O)C1(c1ccccc1)N(O)C(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 5/20 0.35
▸ BACE2 Q9Y5Z0 4/20 0.35
▸ REN P00797 1/20 0.35
▸ APP P05067 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CTSD P07339 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ OPRM1 P35372 1/20 0.33
▸ OPRL1 P41146 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 2/20 0.32
▸ PKM P14618 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18345447 0.86 BACE1 (0.40) BACE1BACE2RENAPPKMT2A
SCHEMBL18345424 0.84 BACE1 (0.35) BACE1BACE2RENAPPKMT2A
SCHEMBL18345419 0.76 MMP9 (0.35) KMT2AMEN1OPRM1ALDH1A1
SCHEMBL18345390 0.72 SMN1; SMN2 (0.48) BACE1BACE2RENAPPKMT2A
SCHEMBL11669193 0.69 LMNA (0.43) BACE1BACE2RENAPPKMT2A
SCHEMBL18345440 0.67 ALDH1A1 (0.35) KMT2AADORA3ADORA2AALDH1A1LMNA
SCHEMBL17290334 0.65 BACE1 (0.41) BACE1BACE2RENAPPKMT2A
SCHEMBL125680 0.62 HSP90AA1 (0.54) KMT2AMEN1ALDH1A1
SCHEMBL18345385 0.61 OPRM1 (0.35) BACE1BACE2KMT2AMEN1OPRM1
SCHEMBL17290797 0.61 BACE1 (0.34) BACE1BACE2RENAPPKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922371-B N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof 约翰斯霍普金斯大学 2022-04-19 — — CN claimed
EP-3313831-B1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF UNIV JOHNS HOPKINS (US) 2021-03-10 — — EP claimed
US-10583141-B2 N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2020-03-10 — — US claimed
US-20180185367-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF NATIONAL SCIENCE FOUNDATION 2018-07-05 — — US claimed
EP-3313831-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF The Johns Hopkins University (US) 2018-05-02 — — EP claimed
WO-2016210392-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2016-12-29 — — WO claimed
CN-107922371-B N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof 约翰斯霍普金斯大学 2022-04-19 — — CN disclosed
EP-3313831-B1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF UNIV JOHNS HOPKINS (US) 2021-03-10 — — EP disclosed
EP-3313831-B1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF UNIV JOHNS HOPKINS (US) 2021-03-10 — — EP disclosed
US-10583141-B2 N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2020-03-10 — — US disclosed
US-20180185367-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF NATIONAL SCIENCE FOUNDATION 2018-07-05 — — US disclosed
US-20180185367-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF NATIONAL SCIENCE FOUNDATION 2018-07-05 — — US disclosed
US-20180185367-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF NATIONAL SCIENCE FOUNDATION 2018-07-05 — — US disclosed
EP-3313831-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF The Johns Hopkins University (US) 2018-05-02 — — EP disclosed
WO-2016210392-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2016-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180185367-A1 N-SUBSTITUTED HYDROXAMIC ACIDS WITH CARBON-BASED LEAVING GROUPS AS EFFICIENT HNO DONORS AND USES THEREOF HAAO, HAO2, HNMT BACE1 4292/4885BACE2 3854/4885REN 2690/4885
US-10583141-B2 N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof HAAO, HAO2, HNMT BACE1 4292/4885BACE2 3854/4885REN 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.